We are delighted to share that Iguazio has been named along with Microsoft, Databricks, Cloudera, Alteryx and others in Now Tech: AI/ML Platforms, Q1 2022, Forrester’s Overview of the Leading AI/ML Platform Providers, by Mike Gualtieri. This report by Forrester Research looks at AI/ML Platform providers, to help technology executives evaluate and select one based on functionality aligned with their needs.
Machine learning is a practice that is evolving and developing every day. Newfound technologies, inventions and methodologies are being introduced to the community on a daily basis. As ML professionals, we can enrich our knowledge and become better at what we do by constantly learning from each other. But with so many resources out there, it might be overwhelming to choose which ones to stay up-to-date on. So where is the best place to start?
Greek philosopher Heraclitus wasn’t talking about the challenge of today’s enterprise IT landscape but the quote certainly fits. From the advent of the first digital computer in the 1940s to the emergence of first public cloud in 2004, the rate of change has only accelerated. In fact, over 60% of corporate data resides in the cloud in 2022, up from 50% last year.
Vaccine development became the top priority for the life sciences industry – delivering new vaccines at unprecedented speed and maneuvering large-scale production processes. Numerous factors helped accelerate the vaccine roll-out including prior research, genome sequencing, jumping the FDA approval queue and a plethora of testing volunteers. So now that we’ve experienced these advancements, how can the industry keep momentum to speed-up innovative solutions across healthcare?
A global leader in pharmaceuticals found themselves faced with a unique spin on a common challenge: Their biopharmaceutical division — responsible for producing vaccines and generating over $1 billion in annual sales — was struggling to turn raw data into trusted insights. Data underlies everything the global pharmaceutical company does, however, without data they can trust, they would be at risk of taking longer to get vaccines to market and incurring higher expenses along the way.
